Abstract：Objective To investigate the therapeutic effect of Xiaojin tablets on breast hyperplasia, and provide evidence for their clinical application.Methods A total of 97 patients with breast hyperplasia admitted to our hospital between February 2016 and May 2017 were selected in this study. The patients were divided into Xiaojin tablet group (n=60) and the control group(n=37)treated with other drugs. The size of breast nodules and the improvement of pain from baseline were compared and analyzed to evaluate the clinical effect in these two groups.Results In the tablet group, the average maximum diameter of breast nodules before treatment was (4.21±1.15)cm, but was(0.93±0.35)cm after treatment. The average VAS prior to treatment was(6.91±1.78), compared with (2.07±0.68)after treatment. In the control group, the average maximum diameter of breast nodules was(4.24±1.07)cm prior to treatment, but was (2.23±0.58)cm after treatment. The average VAS before treatment was (7.56±1.93, but was(3.88±1.41)after treatment. After treatment, the maximum diameter of breast nodules and VAS in both groups were significantly improved. Compared to the control group, the maximum diameter of breast nodules and the pain score in Xiaojin tablet group were significantly decreased, and the difference was statistically significant(P<0.05). Conclusions Xiaojin tablets are quite effective for breast hyperplasia.
2018, Vol. 29 
